Quantcast

Latest MicroIslet Inc. Stories

2008-11-10 18:00:00

SAN DIEGO, Nov. 10, 2008 (GLOBE NEWSWIRE) -- MicroIslet Inc. (OTCBB:MIIS) (http://www.microislet.com), a biotechnology company engaged in the development and commercialization of cell therapies for diabetes, today announced that it filed a voluntary petition for reorganization under Chapter 11 of the U.S. Bankruptcy Code. The company plans to continue operating the business without interruption as management focuses on developing and executing on a corporate restructuring plan. "During the...

2008-10-24 15:00:09

BOTHELL, Wash., Oct. 24 /PRNewswire-FirstCall/ -- BioLife Solutions Inc. (BULLETIN BOARD: BLFS) , a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells, tissues, and organs, today announced that MicroIslet Inc. (BULLETIN BOARD: MIIS) , a biotechnology company engaged in developing and commercializing cellular therapies for patients with diabetes, has adopted HypoThermosol for preserving, transporting, and storing pancreatic source...

2008-08-20 09:01:30

MicroIslet Inc. (OTCBB: MIIS, http://www.microislet.com), a biotechnology company engaged in the development and commercialization of cell therapies for diabetes, has appointed Brian D. Conn to the positions of Vice President Corporate Finance and Chief Financial Officer. Mr. Conn has served as a financial executive in high growth companies for over twenty years. He has extensive experience with M&A and capital transactions. Since 2000, Mr. Conn has held executive positions,...

2008-08-13 15:01:02

MicroIslet Inc. (OTCBB: MIIS, http://www.microislet.com), a biotechnology company engaged in the development and commercialization of cell therapies for diabetes, is pleased to report on the Company's presentation at the XXII International Congress Of The Transplantation Society Meeting, being held August 10-14, 2008, at the Sydney Convention & Exhibition Centre in Sydney, Australia. Drs. Ingrid Stuiver and Amaresh Basu, MicroIslet's Senior Director and Vice President of R&D,...

2008-07-02 09:01:03

MicroIslet Inc. (OTCBB: MIIS, http://www.microislet.com), a biotechnology company engaged in the development and commercialization of cell therapies for diabetes, is pleased to report recent safety and efficacy data. To date, MicroIslet has seen no adverse events attributable to MicroIslet-P(TM) in its animal models. The Company has tested hundreds of rodents and is currently completing a trial with nineteen non-human primates. Eighteen of the nineteen have been tested, and the last...

2007-06-26 12:08:49

SAN DIEGO, June 26, 2007 (PRIME NEWSWIRE) -- MicroIslet, Inc. (OTCBB:MIIS) (the "Company") announced today that Jonathan R. T. Lakey, Ph.D., M.S.M., was named the Company's Chief Scientific Officer and elected to the Company's Board of Directors. Dr. Lakey is a co-developer of the Edmonton Protocol, an internationally recognized treatment for type 1 diabetes. Other new Board members are Keith B. Hoffman, Ph.D., Michael J. Andrews, and Ronald Katz, CPA. The new board members replace Dr....


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related